SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with tianeptine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with tianeptine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 1‐4 weeks compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with trazodone (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with venlafaxine (low certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with agomelatine (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine probably leads to higher failure to remit at endpoint compared with venlafaxine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with venlafaxine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with venlafaxine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with agomelatine (moderate certainty).
1 finding from 1 review